Peptide Library

Skin & matrix research blend

KLOW 80 mg

Research-onlyEvidence: Insufficient

A research blend combining several peptide sequences studied in skin and tissue-matrix contexts. Blends are not registered medicines and have no established clinical evidence base.

Multiple peptide structures in composition — illustrative science visual.

What it is

KLOW refers to a multi-peptide research blend typically combining sequences studied individually in skin and matrix research. As a blend it has no regulatory registration and no dedicated clinical evidence base.

Mechanism being studied

Any mechanistic discussion derives from the individual constituent peptides studied separately in preclinical settings; combined effects are not characterised.

Human evidence

No adequate controlled human evidence exists for this blend.

Safety considerations

Blends compound the uncertainties of each constituent, and quality variability between suppliers is a significant additional risk. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.

Regulatory status

Not a registered medicine. Supply to the public is not authorised. Confirm local law.

Key references

  • Constituent-peptide preclinical literature indexed in PubMed.
  • SAHPRA — unregistered health product warnings.

References are provided as reading directions for professionals. They do not constitute endorsement of any use.

Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.

South Africa — compliance notice

SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.